title: Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study.
abstract: OBJECTIVE
  To compare the effect of captopril with that of placebo on peripheral and hepatic insulin action in essential hypertension, in light of evidence that insulin resistance is associated with cardiovascular risk.
  
  
  METHODS
  Randomized, double-blind, placebo-controlled, crossover trial, with 8 week treatment periods of captopril and placebo preceded and separated by 6 weeks of placebo.
  
  
  METHODS
  Belfast teaching hospital.
  
  
  METHODS
  Eighteen Caucasian nondiabetic patients (10 males), aged under 65 years, with essential hypertension, recruited from general practices in the greater Belfast area.
  
  
  METHODS
  Captopril at 50 mg twice a day or placebo twice a day for two 8 week treatment periods.
  
  
  METHODS
  Peripheral and hepatic insulin sensitivity assessed by glucose clamps.
  
  
  RESULTS
  Fourteen patients completed the study. Mean (+/- SEM) levels of fasting glucose, fasting insulin and postabsorptive hepatic glucose production were similar after captopril and placebo (5.4+/-0.1 versus 5.4+/-0.1 mmol/l, 10.6+/-2.2 versus 9.5+/-1.1 mU/l, 11.2+/-0.6 versus 11.0+/-0.5 mmol/kg per min, respectively). During hyperinsulinaemia, hepatic glucose production was suppressed to comparable levels after both treatments (4.8+/-0.6 versus 4.3+/-0.6 mmol/kg per min) and exogenous glucose infusion rates required to maintain euglycaemia were also similar (30.0+/-2.6 versus 30.3+/-2.6 mmol/kg per min).
  
  
  CONCLUSIONS
  Captopril therapy in uncomplicated essential hypertension has no effect on peripheral or hepatic insulin sensitivity.
authors.affiliation: Sir George E. Clark Metabolic Unit, Royal Victoria Hospital, Belfast, UK.
authors.forename: M I
authors.initials: MI
authors.lastname: Wiggam
authors.forename: S J
authors.initials: SJ
authors.lastname: Hunter
authors.forename: A B
authors.initials: AB
authors.lastname: Atkinson
authors.forename: C N
authors.initials: CN
authors.lastname: Ennis
authors.forename: J S
authors.initials: JS
authors.lastname: Henry
authors.forename: J N
authors.initials: JN
authors.lastname: Browne
authors.forename: B
authors.initials: B
authors.lastname: Sheridan
authors.forename: P M
authors.initials: PM
authors.lastname: Bell
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D018592:Cross-Over Studies; D003971:Diastole; D004311:Double-Blind Method; D005215:Fasting; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D007328:Insulin / Q000097:blood*; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D012039:Regional Blood Flow / Q000187:drug effects; D013599:Systole
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D008076:Cholesterol, HDL; D007328:Insulin; D002784:Cholesterol; D002216:Captopril